BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Burstein HJ, Curigliano G, Thürlimann B, Weber WP, Poortmans P, Regan M, Senn HJ, Winer EP, Gnant M; Panelists of the St Gallen Consensus Conference. CUSTOMIZING LOCAL AND SYSTEMIC THERAPIES FOR WOMEN WITH EARLY BREAST CANCER: The St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol 2021:S0923-7534(21)02104-9. [PMID: 34242744 DOI: 10.1016/j.annonc.2021.06.023] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
Number Citing Articles
1 Kerr AJ, Dodwell D, Mcgale P, Holt F, Duane F, Mannu G, Darby SC, Taylor CW. Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality. Cancer Treatment Reviews 2022. [DOI: 10.1016/j.ctrv.2022.102375] [Reference Citation Analysis]
2 Magnoni F, Alessandrini S, Alberti L, Polizzi A, Rotili A, Veronesi P, Corso G. Breast Cancer Surgery: New Issues. Curr Oncol 2021;28:4053-66. [PMID: 34677262 DOI: 10.3390/curroncol28050344] [Reference Citation Analysis]
3 Leonardi MC, Arrobbio C, Gandini S, Volpe S, Colombo F, La Rocca E, Galimberti V, Kahler-Ribeiro-Fontana S, Fodor C, Dicuonzo S, Rojas DP, Zerella MA, Morra A, Montagna E, Colleoni M, Mazzarol G, Travaini LL, Zaffaroni M, Veronesi P, Orecchia R, Jereczek-Fossa BA. Predictors of positive axillary non-sentinel lymph nodes in breast cancer patients with positive sentinel lymph node biopsy after neoadjuvant systemic therapy. Radiother Oncol 2021;163:128-35. [PMID: 34461184 DOI: 10.1016/j.radonc.2021.08.013] [Reference Citation Analysis]
4 Gwark S, Noh WC, Ahn SH, Lee ES, Jung Y, Kim LS, Han W, Nam SJ, Gong G, Kim SO, Kim HJ. Axillary Lymph Node Dissection Rates and Prognosis From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer. Front Oncol 2021;11:741120. [PMID: 34660302 DOI: 10.3389/fonc.2021.741120] [Reference Citation Analysis]
5 Dellapasqua S, Trillo Aliaga P, Munzone E, Bagnardi V, Pagan E, Montagna E, Cancello G, Ghisini R, Sangalli C, Negri M, Mazza M, Iorfida M, Cardillo A, Sciandivasci A, Bianco N, De Maio AP, Milano M, Campennì GM, Sansonno L, Viale G, Morra A, Leonardi MC, Galimberti V, Veronesi P, Colleoni M. Pegylated Liposomal Doxorubicin (Caelyx®) as Adjuvant Treatment in Early-Stage Luminal B-like Breast Cancer: A Feasibility Phase II Trial. Current Oncology 2021;28:5167-78. [DOI: 10.3390/curroncol28060433] [Reference Citation Analysis]
6 Xu A, Chu X, Zhang S, Zheng J, Shi D, Lv S, Li F, Weng X. Prediction Breast Molecular Typing of Invasive Ductal Carcinoma Based on Dynamic Contrast Enhancement Magnetic Resonance Imaging Radiomics Characteristics: A Feasibility Study. Front Oncol 2022;12:799232. [DOI: 10.3389/fonc.2022.799232] [Reference Citation Analysis]
7 Tarantino P, Burstein HJ, Lin NU, Krop IE, Winer EP, Schnitt SJ, Hamilton EP, Hurvitz SA, Rugo HS, Curigliano G, Tolaney SM. Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib? Ann Oncol 2021:S0923-7534(21)04877-8. [PMID: 34942341 DOI: 10.1016/j.annonc.2021.12.004] [Reference Citation Analysis]
8 Schmidt M, Heimes AS. Immunomodulating Therapies in Breast Cancer-From Prognosis to Clinical Practice. Cancers (Basel) 2021;13:4883. [PMID: 34638367 DOI: 10.3390/cancers13194883] [Reference Citation Analysis]
9 Morganti S, Marra A, Crimini E, D’amico P, Zagami P, Curigliano G. Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation? Breast Cancer Res Treat. [DOI: 10.1007/s10549-022-06535-1] [Reference Citation Analysis]
10 Kaidar-person O, Poortmans P. Proud about PRADA: radiotherapy before deep inferior epigastric perforator flap reconstruction. The Lancet Oncology 2022. [DOI: 10.1016/s1470-2045(22)00195-4] [Reference Citation Analysis]
11 Antonarelli G, Valenza C, Mayer EL, Loibl S, Curigliano G. Cyclin dependent kinase 4/6 inhibitors in early breast cancer: what is the role of Ki-67? The Lancet Oncology 2022;23:325-8. [DOI: 10.1016/s1470-2045(21)00756-7] [Reference Citation Analysis]
12 Keup C, Kimmig R, Kasimir-bauer S. Combinatorial Power of cfDNA, CTCs and EVs in Oncology. Diagnostics 2022;12:870. [DOI: 10.3390/diagnostics12040870] [Reference Citation Analysis]
13 Tan Q, Yin S, Zhou D, Chi Y, Man X, Li H. Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer. Front Oncol 2022;12:779786. [DOI: 10.3389/fonc.2022.779786] [Reference Citation Analysis]
14 Minichsdorfer C, Fuereder T, Leutner M, Singer CF, Kacerovsky-Strobl S, Egle D, Greil R, Balic M, Fitzal F, Pfeiler G, Frantal S, Bartsch R, Gnant M. Effect of concomitant statin treatment in postmenopausal patients with hormone receptor-positive early-stage breast cancer receiving adjuvant denosumab or placebo: a post hoc analysis of ABCSG-18. ESMO Open 2022;7:100426. [PMID: 35334418 DOI: 10.1016/j.esmoop.2022.100426] [Reference Citation Analysis]
15 Wu Y, Han Y, Li Q, Zhang P, Yuan P, Luo Y, Fan Y, Chen S, Cai R, Li Q, Xu H, Wang Y, Ma F, Wang J, Xu B. Predictive value of topoisomerase II alpha protein for clinicopathological characteristics and prognosis in early breast cancer. Breast Cancer Res Treat 2022. [PMID: 35297009 DOI: 10.1007/s10549-022-06559-7] [Reference Citation Analysis]
16 Griguolo G, Bottosso M, Vernaci G, Miglietta F, Dieci MV, Guarneri V. Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2- breast cancer: Available evidence and clinical implications. Cancer Treat Rev 2022;102:102323. [PMID: 34896969 DOI: 10.1016/j.ctrv.2021.102323] [Reference Citation Analysis]
17 Bi Z, Qiu PF, Zhang Y, Song XG, Chen P, Xie L, Wang YS, Song XR. A Three lncRNA Set: AC009975.1, POTEH-AS1 and AL390243.1 as Nodal Efficacy Biomarker of Neoadjuvant Therapy for HER-2 Positive Breast Cancer. Front Oncol 2021;11:779140. [PMID: 34938660 DOI: 10.3389/fonc.2021.779140] [Reference Citation Analysis]
18 Zhao W, Li X, Wang W, Chen B, Wang L, Zhang N, Wang Z, Yang Q. Association of Preoperative Serum Levels of CEA and CA15-3 with Molecular Subtypes of Breast Cancer. Dis Markers 2021;2021:5529106. [PMID: 34621407 DOI: 10.1155/2021/5529106] [Reference Citation Analysis]
19 Chen N, Zhang XY, Ma LL, Zhao GD, Yan YX. Trends of cancer mortality in Xi'an City, China: 2005-2020. J Cancer Res Clin Oncol 2022. [PMID: 35567625 DOI: 10.1007/s00432-022-04046-6] [Reference Citation Analysis]
20 Kaidar-person O, Weber WP, Kühn T, Poortmans P. The forgotten node: Axillary surgery mandates expertise. European Journal of Surgical Oncology 2022. [DOI: 10.1016/j.ejso.2022.05.012] [Reference Citation Analysis]
21 de Boniface J, Frisell J, Kühn T, Wiklander-Bråkenhielm I, Dembrower K, Nyman P, Zouzos A, Gerber B, Reimer T, Hartmann S. False-negative rate in the extended prospective TATTOO trial evaluating targeted axillary dissection by carbon tattooing in clinically node-positive breast cancer patients receiving neoadjuvant systemic therapy. Breast Cancer Res Treat 2022. [PMID: 35451733 DOI: 10.1007/s10549-022-06588-2] [Reference Citation Analysis]
22 Catanuto G, Rocco N, Maglia A, Barry P, Karakatsanis A, Heil J, Karakatsanis A, Weber WP, Gonzalez E, Chatterjee A, Urban C, Sund M, Paulinelli RR, Markopoulos C, Rubio IT, Masannat YA, Meani F, Koppiker CB, Holcombe C, Benson JR, Dietz JR, Walker M, Mátrai Z, Shaukat A, Gulluoglu B, Brenelli F, Fitzal F, Mele M, Sgroi G, Russo G, Pappalardo F, Nava M. Text mining and word embedding for classification of decision making variables in breast cancer surgery. European Journal of Surgical Oncology 2022. [DOI: 10.1016/j.ejso.2022.03.002] [Reference Citation Analysis]
23 Gnant M, Dueck AC, Frantal S, Martin M, Burstein HJ, Greil R, Fox P, Wolff AC, Chan A, Winer EP, Pfeiler G, Miller KD, Colleoni M, Suga JM, Rubovsky G, Bliss JM, Mayer IA, Singer CF, Nowecki Z, Hahn O, Thomson J, Wolmark N, Amillano K, Rugo HS, Steger GG, Hernando Fernández de Aránguiz B, Haddad TC, Perelló A, Bellet M, Fohler H, Metzger Filho O, Jallitsch-Halper A, Solomon K, Schurmans C, Theall KP, Lu DR, Tenner K, Fesl C, DeMichele A, Mayer EL; PALLAS groups and investigators. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). J Clin Oncol 2021;:JCO2102554. [PMID: 34874182 DOI: 10.1200/JCO.21.02554] [Reference Citation Analysis]
24 Campani V, Salaroglio IC, Nele V, Kopecka J, Bernkop-schnürch A, Riganti C, De Rosa G. Targeted Self-Emulsifying Drug Delivery Systems to Restore Docetaxel Sensitivity in Resistant Tumors. Pharmaceutics 2022;14:292. [DOI: 10.3390/pharmaceutics14020292] [Reference Citation Analysis]
25 Trapani D, Franzoi MA, Burstein HJ, Carey LA, Delaloge S, Harbeck N, Hayes DF, Kalinsky K, Pusztai L, Regan MM, Sestak I, Spanic T, Sparano J, Jezdic S, Cherny N, Curigliano G, Andre F. Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification. Ann Oncol 2022:S0923-7534(22)00669-X. [PMID: 35550723 DOI: 10.1016/j.annonc.2022.03.273] [Reference Citation Analysis]
26 Cong B, Wang Y. Controversial Opinion of “All pCRs are the Same” in St. Gallen International Consensus Guidelines 2021. CMAR 2022;Volume 14:1019-21. [DOI: 10.2147/cmar.s345102] [Reference Citation Analysis]
27 Corso G. Pleiotropic cancer manifestations of germline CDH1 mutations: Risks and management. Journal of Surgical Oncology. [DOI: 10.1002/jso.26847] [Reference Citation Analysis]
28 Yang L, Jia J, Li S. Advances in the Application of Exosomes Identification Using Surface-Enhanced Raman Spectroscopy for the Early Detection of Cancers. Front Bioeng Biotechnol 2022;9:808933. [DOI: 10.3389/fbioe.2021.808933] [Reference Citation Analysis]
29 Harvey-Jones E, Vinas Villaro G, Tutt A. New Roles of Poly(ADP-Ribose) Polymerase Inhibitors in the Treatment of Breast Cancer. Cancer J 2021;27:441-56. [PMID: 34904807 DOI: 10.1097/PPO.0000000000000559] [Reference Citation Analysis]
30 Li X, Zhu H, Sun K, Chai W, Fu C, Yan F. Is simultaneous multi-slice readout-segmented echo-planar imaging valuable for predicting molecular subtypes of breast cancer? European Journal of Radiology 2022;150:110232. [DOI: 10.1016/j.ejrad.2022.110232] [Reference Citation Analysis]